PRIO pharma (Pharmaceutical Research Initiative in Open innovation) enables drug development innovations by co-creation. It is the latest addition to our scope of opportunities for companies to accelerate the development of new drugs for a healthier society.

PRIO pharma identifies novel pharmaceutical co-creation opportunities, allowing the Pivot Park Community to share and exploit their capacities and expertise by embracing valuable collaborations with partners from within and outside of the campus. PRIO pharma does this by identifying (inter)national drug development opportunities and concomitant financing opportunities. These activities should translate into new consortia fostering open innovation, whilst continuously protecting the IP position of the participating entities.

PRIO pharma was launched at the Bio Europe 2016 in Cologne, the perfect place to reach relevant stakeholders including: entrepreneurial academic leaders, CROs, pharma and venture capitalists. Several project openings have been created already, which will be reported on over time. Meanwhile, we invite you to share and discuss about possibilities on how PRIO pharma can properly support your business activities. For info contact us via or look at our webpage.